Head-To-Head Analysis: Whitehawk Therapeutics (WHWK) versus Its Peers

Whitehawk Therapeutics (NASDAQ:WHWK) is one of 450 public companies in the “Pharmaceutical Preparations” industry, but how does it compare to its competitors? We will compare Whitehawk Therapeutics to related businesses based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, analyst recommendations and risk.

Risk & Volatility

Whitehawk Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics’ competitors have a beta of 10.34, suggesting that their average stock price is 934% more volatile than the S&P 500.

Insider and Institutional Ownership

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Whitehawk Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	99.42%	-75.99%	-68.57%
Whitehawk Therapeutics Competitors	-2,625.49%	-359.63%	-43.39%

Analyst Recommendations

This is a summary of current ratings for Whitehawk Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	1	0	0	1.50
Whitehawk Therapeutics Competitors	4784	9959	15994	370	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 101.98%. Given Whitehawk Therapeutics’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Whitehawk Therapeutics has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Whitehawk Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Whitehawk Therapeutics	$25.98 million	-$63.69 million	-40.17
Whitehawk Therapeutics Competitors	$439.19 million	-$68.89 million	-9.47

Whitehawk Therapeutics’ competitors have higher revenue, but lower earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Whitehawk Therapeutics competitors beat Whitehawk Therapeutics on 8 of the 13 factors compared.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.